** Shares of ProKidney PROK.O rise 62.4% to $1.25 cents premarket
** Co says its drug, rilparencel, showed improvement in kidney function decline in patients with chronic kidney disease and diabetes during mid-stage trial
** PROK has upcoming meeting with Food and Drug Administration to confirm approach of drug's planned late-stage trial
** Up to last close, stock down 64% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))